These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31418415)

  • 1. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens.
    El Kassas M; Alboraie M; Naguib M; Omar H; Tahan AE; Moaz I; Abdellah M; Ezzat S; Wifi MN; Sherief AF; Eltabbakh M; Abdelsalam L; Eissa AH; Omran D
    Turk J Gastroenterol; 2019 Aug; 30(8):708-713. PubMed ID: 31418415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals.
    Yoh K; Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Aizawa N; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29057827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Tabernilla A; Grandal M; Pernas B; Castro-Iglesias A; Rodríguez-Osorio I; Mena A; Delgado M; Cid P; Pedreira JD; Poveda E
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):781-785. PubMed ID: 28410351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
    Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
    J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
    PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
    El Kassas M; Alboraie M; Omran D; Salaheldin M; Wifi MN; ElBadry M; El Tahan A; Ezzat S; Moaz E; Farid AM; Omar H; Abouelkhair M; Afify S; Elsaeed K; Shazly Y; Doss W; Esmat G
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1265-1272. PubMed ID: 29757684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response.
    Fernandes FF; Piedade J; Guimaraes L; Nunes EP; Chaves U; Goldenzon RV; Cardoso SW; Duarte J; Grinsztejn B; Veloso VG; Pereira G; Perazzo H
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2187-2195. PubMed ID: 31062880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct acting antivirals failure: cause and retreatment options.
    Parlati L; Pol S
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.
    McKnight AH; Townsend ML; Hashem MG; Naggie S; Park LP; Britt RB
    Ann Pharmacother; 2020 Nov; 54(11):1057-1064. PubMed ID: 32406244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection.
    Ichikawa T; Miyaaki H; Miuma S; Motoyoshi Y; Narita S; Toda S; Takahashi Y; Honda T; Yajima H; Uehara R; Hino N; Hori T; Hirata R; Taura N; Nakao K
    Intern Med; 2019 May; 58(9):1209-1215. PubMed ID: 30626818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
    Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
    J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.